Chadi Nabhan, MD, MBA, FACP

$Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States$

Research Reports

Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States

02/18/2020

Andrew J. Klink , PhD, MPH;

Anna G. Purdum , PharmD, MS;

Chadi Nabhan , MD, MBA, FACP;

Bruce A. Feinberg , DO;

Choo Hyung Lee , MS;

Yin Yang , MS;

JaLyna Laney , RN, OCN;

Abstract: Given new therapeutic advances that are potentially curative in diffuse large B-cell lymphoma (DLBCL), it is important to understand what has been observed to date in this population to assess improvement...

...

02/18/2020

Journal of Clinical Pathways

Counterpoint

Understanding Provider Perceptions Is Key to Utilization and Uptake of CAR-T Therapy

04/17/2018

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

The potential impact of chimeric antigen receptor T-cell (CAR-T) therapies should not be underestimated, nor should their complexity. There is much to consider when reprogramming patients’ own immune cells. As most...

The...

04/17/2018

Journal of Clinical Pathways

From the Field

Mock Clinical Pathways: Exploring the Process of Developing a Pathway for Metastatic Breast Cancer

02/15/2018

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care delivery, allowing for cost reduction as well as more predictable, measurable, and accountable outcomes. At the 2nd Annual...

Abstract: Clinical...

02/15/2018

Journal of Clinical Pathways